• Citer

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.

par Awada, Ahmad ;Dumez, Herlinde;Hendlisz, Alain ;Wolter, P;Besse-Hammer, Tatiana;Uttenreuther-Fischer, Martina;Stopfer, P;Fleischer, Frank;Piccart-Gebhart, Martine ;Schöffski, Patrick
Référence Investigational new drugs, 31, 3, page (734-741)
Publication Publié, 2013-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Auteur:	Awada, Ahmad; Dumez, Herlinde; Hendlisz, Alain; Wolter, P; Besse-Hammer, Tatiana; Uttenreuther-Fischer, Martina; Stopfer, P; Fleischer, Frank; Piccart-Gebhart, Martine; Schöffski, Patrick
Informations sur la publication:	Investigational new drugs, 31, 3, page (734-741)
Statut de publication:	Publié, 2013-06
Sujet CREF:	Cancérologie
Mots-clés:	Afatinib
	BIBW 2992
	Epidermal growth factor receptor
	Pharmacokinetics
	Phase I
	Tyrosine kinase inhibitor
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics
	Antineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effects -- pharmacokinetics
	Drug Administration Schedule
	Female
	Gastrointestinal Diseases -- chemically induced
	Humans
	Male
	Maximum Tolerated Dose
	Middle Aged
	Neoplasms -- blood -- drug therapy
	Quinazolines -- administration & dosage -- adverse effects -- pharmacokinetics
	Skin Diseases -- chemically induced
	Taxoids -- administration & dosage -- adverse effects -- pharmacokinetics
Note générale:	Journal Article
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6997
	info:doi/10.1007/s10637-012-9880-0
	info:scp/84879092054
	info:pmid/23161334
	PMC3644400